Pasar al contenido principal

LEVELING UP IN GB THERAPY MONITORING: TOWARDS A UNIVERSAL BIOMARKER OF IMMUNE SYSTEM ATTACK

PID2020-113058GB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 17
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Targeting Retinaldehyde Dehydrogenases to Enhance Temozolomide Therapy in Glioblastoma

  • Jiménez, Rafael|||0000-0003-4103-8219
  • Constantinescu, Andrada
  • Yazir, Muhube
  • Alfonso Triguero, Paula|||0000-0002-6554-5656
  • Pequerul Pavón, Raquel|||0000-0002-0008-975X
  • Parés i Casasampera, Xavier|||0000-0002-5071-9465
  • Pérez-Alea, Mileidys|||0000-0002-8739-8087
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Farrés, Jaume|||0000-0001-9069-3987
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
Glioblastoma (GB) is an aggressive malignant central nervous system tumor that is currently incurable. One of the main pitfalls of GB treatment is resistance to the chemotherapeutic standard of care, temozolomide (TMZ). The role of aldehyde dehydrogenases (ALDHs) in the glioma stem cell (GSC) subpopulation has been related to chemoresistance. ALDHs take part in processes such as cell proliferation, differentiation, invasiveness or metastasis and have been studied as pharmacological targets in cancer treatment. In the present work, three novel α,β-acetylenic amino thiolester compounds, with demonstrated efficacy as ALDH inhibitors, were tested in vitro on a panel of six human GB cell lines and one murine GB cell line. Firstly, the expression of the ALDH1A isoforms was assessed, and then inhibitors were tested for their cytotoxicity and their ability to inhibit cellular ALDH activity. Drug combination assays with TMZ were performed, as well as an assessment of the cell death mechanism and generation of ROS. A knockout of several ALDH genes was carried out in one of the human GB cell lines, allowing us to discuss their role in cell proliferation, migration capacity and resistance to treatment. Our results strongly suggest that ALDH inhibitors could be an interesting approach in the treatment of GB, with EC50 values in the order of micromolar, decreasing ALDH activity in GB cell lines to 40-50%.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Synthesis and Relaxivity study of amino acid-branched radical dendrimers as MRI contrast agents for potential brain tumor imaging

  • Wu, Yufei
  • Lloveras Monserrat, Vega|||0000-0002-9653-3340
  • Lope-Piedrafita, Silvia|||0000-0002-8127-6425
  • Mulero-Acevedo, Marta|||0000-0002-3600-8907
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Vidal-Gancedo, José|||0000-0002-1853-9675
This study introduces a series of water-soluble radical dendrimers (G0 to G5) as promising magnetic resonance imaging (MRI) contrast agents that could potentially address clinical safety concerns associated with current gadolinium-based contrast agents. By using a simplified synthetic approach based on a cyclotriphosphazene core and lysine-derived branching units, we successfully developed a G5 dendrimer containing up to 192 units of 2,2,6,6-Tetramethylpiperidinyloxy (TEMPO) radical. This synthesis offers advantages including ease of preparation, purification, and tunable water solubility through the incorporation of glutamic acid anion residues. Comprehensive characterization using 1H NMR, FT-IR, and SEC-HPLC confirmed the dendrimers' structures and purity. Electron paramagnetic resonance (EPR) spectroscopy revealed that TEMPO groups in higher generation dendrimers exhibited decreased mobility and stronger spin exchange in their local environments. In vitro MRI showed that relaxivity (r1) increased with higher dendrimer generations, with G5 exhibiting an exceptionally high r1 of over 24 mM-1s-1. Molecular dynamics simulations provided crucial insights into structure-property relationships, revealing the importance of water accessibility to TEMPO groups for enhancing relaxivity. Vero cell viability assay demonstrated G3 and G3.5 have good biocompatibility. In vivo MRI experiments in mice demonstrated that G3.5 was excreted through the kidneys and selectively accumulated in glioblastoma tumors. Statement of significance: This study explores a class of MRI contrast agents based on organic radical dendrimers as a potential alternative to gadolinium-based agents. We present a simplified synthesis method for water-soluble dendrimers containing up to 192 TEMPO radical units-the highest number achieved to date for this class of compounds-resulting in record-high relaxivity values. Our approach offers easier preparation, purification, and tunable water solubility, representing an improvement over existing methods. Through combined experimental and computational studies, we provide insights into the structure-property relationships governing relaxivity. In vivo experiments demonstrate the dendrimers' potential for glioblastoma imaging, with predominantly renal excretion. This work represents a step towards developing metal-free MRI contrast agents with promising relaxivity and biocompatibility, potentially opening new avenues for diagnostic imaging research.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Metal-Free Radical Dendrimers as MRI Contrast Agents for Glioblastoma Diagnosis: Ex Vivo and In Vivo Approaches

  • Zhang, Songbai
  • Lloveras, Vega
  • Lope Piedrafita, Silvia
  • Calero Pérez, Pilar
  • Wu, Shuang
  • Candiota, Ana Paula
  • Vidal Gancedo, José
Simultaneously being a nonradiative and noninvasive technique makes magnetic resonance imaging (MRI) one of the highly required imaging approaches for the early diagnosis and follow-up of tumors, specifically for brain cancer. Paramagnetic gadolinium (Gd)-based contrast agents (CAs) are the most widely used ones in brain MRI acquisitions with special interest when assessing blood-brain barrier (BBB) integrity, a characteristic of high-grade tumors. However, alternatives to Gd-based contrast agents (CAs) are highly required to overcome their established toxicity. Organic radicals anchored on a dendrimer macromolecule surface (radical dendrimers) are promising alternatives since they also exhibit paramagnetic properties and can act as T1 CAs like Gd-based CAs while being organic species (mitigating concerns about toxic metal accumulation). Here, we studied the third generation of a water-soluble family of poly(phosphorhydrazone) radical dendrimers, with 48 PROXYL radical units anchored on their branches, exploring their potential of ex vivo and in vivo contrast enhancement in brain tumors (in particular, of immunocompetent, orthotopic GL261 murine glioblastoma (GB)). Remarkably, this radical species provides suitable contrast enhancement on murine GL261 GB tumors, which was comparable to that of commercial Gd-based CAs (at standard dose 0.1 mmol/kg), even at its 4 times lower administered dose (0.025 mmol/kg). Importantly, no signs of toxicity were detected in vivo. In addition, it showed a selective accumulation in brain tumor tissues, exhibiting longer retention within the tumor, which allows performing imaging acquisition over longer time frames (≥2.5 h) as opposed to Gd chelates. Finally, we observed high stability of the radicals in biological media, on the order of hours instead of minutes, characteristic of the isolated radicals. All of these features allow us to suggest that the G3-Tyr-PROXYL-ONa radical dendrimer could be a viable alternative to metal-based MRI contrast agents, particularly on MRI analysis of GB, representing, to the best of our knowledge, the first case of organic radical species used for this purpose and one of the very few examples of these types of radical species working as MRI CAs in vivo., This work was supported by Ministerio de Ciencia e Innovación MICINN (PID2019-105622RB-I00, CTQ2017-90596-REDT, Severo Ochoa FUNMAT-FIP-2018, and FUNFUTURE-FIP-2020 projects), CSIC (Intramural CSIC project 201760E080), and Generalitat de Catalunya (2017 SGR918). ICMAB acknowledges Spanish MICINN through the Severo Ochoa Centres of Excellence Programme Grants SEV-2015-0496 and CEX2019-000917-S. The work was also funded by Centro de Investigación Biomédica en Red – Bioingeniería, Biomateriales y Nanomedicina, an initiative of the Instituto de Salud Carlos III (Spain) cofunded by EU Fondo Europeo de Desarrollo Regional (FEDER). A.P.C. received funding from the ATTRACT project funded by the EC under Grant Agreement 777222 and the MICINN grant TRIBUTE (PID2020-113058GB-I00/AEI/10.13039/501100011033)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2019-000917-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help?

  • Ruiz Molina, Daniel
  • Mao, Xiaoman
  • Alfonso Triguero, Paula
  • Lorenzo, Julia
  • Bruna, Jordi
  • Yuste, Víctor J.
  • Candiota, Ana Paula
  • Novio, Fernando
Glioblastoma multiforme (GB) is the most aggressive and frequent primary malignant tumor in the central nervous system (CNS), with unsatisfactory and challenging treatment nowadays. Current standard of care includes surgical resection followed by chemotherapy and radiotherapy. However, these treatments do not much improve the overall survival of GB patients, which is still below two years (the 5-year survival rate is below 7%). Despite various approaches having been followed to increase the release of anticancer drugs into the brain, few of them demonstrated a significant success, as the blood brain barrier (BBB) still restricts its uptake, thus limiting the therapeutic options. Therefore, enormous efforts are being devoted to the development of novel nanomedicines with the ability to cross the BBB and specifically target the cancer cells. In this context, the use of nanoparticles represents a promising non-invasive route, allowing to evade BBB and reducing systemic concentration of drugs and, hence, side effects. In this review, we revise with a critical view the different families of nanoparticles and approaches followed so far with this aim., This work was supported by grant RTI2018-098027-B-C21, RTI2018-098027-B-C22, and PID2020-113058GB-I00 funded by MCIN/AEI/10.13039/501100011033, by ERDF A way of making Europe and by PI21/00181 from the Instituto Carlos III. This work was also supported by “Metalfármacos multifuncionales para el diagnóstico y la terapia”, through grant RED2018-102471-T, funded by MCIN/AEI/10.13039/501100011033. The ICN2 and IDIBELL are funded by the CERCA programme/Generalitat de Catalunya. The ICN2 is supported by the Severo Ochoa Centres of Excellence programme, grant SEV-2017-0706, funded by MCIN/AEI/10.13039/501100011033. COST is kindly acknowledged for stimulating scientific discussion and financial support via the Cost Action CA 17140 “Cancer nanomedicine from the bench to the bedside”. A.P.C. received funding from the ATTRACT project funded by the EC under Grant Agreement 777222. This work was also supported by the Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN [http://www.ciber-bbn.es/en], CB06/01/0010), an initiative of the Instituto de Salud Carlos III (Spain). The PhD program of X.M. was supported by the La Caixa-Severo Ochoa International PhD Fellowship.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Intranasal Administration of Catechol-Based Pt(IV) Coordination Polymer Nanoparticles for Glioblastoma Therapy

  • Mao, Xiaoman
  • Calero Pérez, Pilar
  • Montpeyó, David
  • Bruna, Jordi
  • Yuste, Víctor J.
  • Candiota, Ana Paula
  • Lorenzo, Julia
  • Novio, Fernando
  • Ruiz Molina, Daniel
Cisplatin has been described as a potent anticancer agent for decades. However, in the case of glioblastomas, it is only considered a rescue treatment applied after the failure of second-line treatments. Herein, based on the versatility offered by coordination chemistry, we engineered nanoparticles by reaction of a platinum (IV) prodrug and iron metal ions showing in vitro dual pH-and redox-sensitivity, controlled release and comparable cytotoxicity to cisplatin against HeLa and GL261 cells. In vivo intranasal administration in orthotopic preclinical GL261 glioblastoma tumor-bearing mice demonstrated increased accumulation of platinum in tumors, leading in some cases to complete cure and prolonged survival of the tested cohort. This was corroborated by a magnetic resonance imaging follow-up, thus opening new opportunities for intranasal glioblastoma therapies while minimizing side effects. The findings derived from this research showed the potentiality of this approach as a novel therapy for glioblastoma treatment., This work was supported by grant RTI2018-098027-B-C21, RTI2018-098027-B-C22 and PID2020-113058GB-I00 funded by MCIN/AEI/10.13039/501100011033 and by ERDF A way of making Europe. With the support from “Metalfármacos multifuncionales para el diagnóstico y la terapia” with grant RED2018-102471-T funded by MCIN/AEI/10.13039/501100011033. The ICN2 is funded by the CERCA programme/Generalitat de Catalunya. The ICN2 is supported by the Severo Ochoa Centres of Excellence programme, grant SEV-2017-0706 funded by MCIN/AEI/10.13039/501100011033. COST is kindly acknowledged for stimulating scientific discussion and financial support via the Cost Action CA 17140 “Cancer nanomedicine from the bench to the bedside”. A.P.C. received funding from the ATTRACT project funded by the EC under Grant Agreement 777222. Work also supported by Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN [http://www.ciber-bbn.es/en, accessed on 24 March 2022], CB06/01/0010), an initiative of the Instituto de Salud Carlos III (Spain). The PhD program of X.M. was supported by the La Caixa-Severo Ochoa International PhD Fellowship. We acknowledge the UAB Predoctoral training program (14ª Convocatoria PIF-19612, predoctoral fellowships for P.C.-P)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synthesis and Validation of a Bioinspired Catechol-Functionalized Pt(IV) Prodrug for Preclinical Intranasal Glioblastoma Treatment

  • Mao, Xiaoman
  • Wu, Shuang
  • Calero Pérez, Pilar
  • Candiota, Ana Paula
  • Alfonso Triguero, Paula
  • Bruna, Jordi
  • Yuste, Víctor J.
  • Lorenzo, Julia
  • Novio, Fernando
  • Ruiz Molina, Daniel
Glioblastoma is the most malignant and frequently occurring type of brain tumors in adults. Its treatment has been greatly hampered by the difficulty to achieve effective therapeutic concentration in the tumor sites due to its location and the blood–brain barrier. Intranasal administration has emerged as an alternative for drug delivery into the brain though mucopenetration, and rapid mucociliary clearance still remains an issue to be solved before its implementation. To address these issues, based on the intriguing properties of proteins secreted by mussels, polyphenol and catechol functionalization has already been used to promote mucopenetration, intranasal delivery and transport across the blood–brain barrier. Thus, herein we report the synthesis and study of complex 1, a Pt(IV) prodrug functionalized with catecholic moieties. This complex considerably augmented solubility in contrast to cisplatin and showed a comparable cytotoxic effect on cisplatin in HeLa, 1Br3G and GL261 cells. Furthermore, preclinical in vivo therapy using the intranasal administration route suggested that it can reach the brain and inhibit the growth of orthotopic GL261 glioblastoma. These results open new opportunities for catechol-bearing anticancer prodrugs in the treatment for brain tumors via intranasal administration., This work was supported by grant RTI2018-098027-B-C21, RTI2018-098027-B-C22 and PID2020-113058GB-I00 funded by MCIN/AEI/10.13039/501100011033 and by ERDF’s A way of making Europe as well as with the support from “Metalfármacos multifuncionales para el diagnóstico y la terapia” with grant RED2018-102471-T funded by MCIN/AEI/10.13039/501100011033. The ICN2 is funded by the CERCA programme/Generalitat de Catalunya. The ICN2 is supported by the Severo Ochoa Centres of Excellence programme, and grant SEV-2017-0706 is funded by MCIN/AEI/10.13039/501100011033. COST is kindly acknowledged for stimulating scientific discussion and financial support via the Cost Action CA 17140 “Cancer nanomedicine from the bench to the bedside”. A.P.C. received funding from the ATTRACT project funded by the EC under grant agreement 777222. The work was also supported by Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN [http://www.ciber-bbn.es/en, accessed on 24 November 2021], CB06/01/0010), an initiative of the Instituto de Salud Carlos III (Spain). The PhD program of X.M. was supported by the La Caixa-Severo Ochoa International PhD Fellowship. We acknowledge the UAB predoctoral training program (14th Convocatoria PIF-19612, predoctoral fellowships for P.C.-P) and China Scholarship Council (predoctoral fellowship 201606990027 for S.W.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Platinum-based nanoformulations for glioblastoma treatment: the resurgence of platinum drugs?

  • Alfonso Triguero, Paula
  • Lorenzo, Julia
  • Candiota, Ana Paula
  • Arús, Carles
  • Ruiz Molina, Daniel
  • Novio, Fernando
This article belongs to the Special Issue Current Review in Nanofabrication and Nanomanufacturing., Current therapies for treating Glioblastoma (GB), and brain tumours in general, are inefficient and represent numerous challenges. In addition to surgical resection, chemotherapy and radiotherapy are presently used as standards of care. However, treated patients still face a dismal prognosis with a median survival below 15–18 months. Temozolomide (TMZ) is the main chemotherapeutic agent administered; however, intrinsic or acquired resistance to TMZ contributes to the limited efficacy of this drug. To circumvent the current drawbacks in GB treatment, a large number of classical and non-classical platinum complexes have been prepared and tested for anticancer activity, especially platinum (IV)-based prodrugs. Platinum complexes, used as alkylating agents in the anticancer chemotherapy of some malignancies, are though often associated with severe systemic toxicity (i.e., neurotoxicity), especially after long-term treatments. The objective of the current developments is to produce novel nanoformulations with improved lipophilicity and passive diffusion, promoting intracellular accumulation, while reducing toxicity and optimizing the concomitant treatment of chemo-/radiotherapy. Moreover, the blood–brain barrier (BBB) prevents the access of the drugs to the brain and accumulation in tumour cells, so it represents a key challenge for GB management. The development of novel nanomedicines with the ability to (i) encapsulate Pt-based drugs and pro-drugs, (ii) cross the BBB, and (iii) specifically target cancer cells represents a promising approach to increase the therapeutic effect of the anticancer drugs and reduce undesired side effects. In this review, a critical discussion is presented concerning different families of nanoparticles able to encapsulate platinum anticancer drugs and their application for GB treatment, emphasizing their potential for increasing the effectiveness of platinum-based drugs., This research was supported by grant PID2021-127983OB-C21, PID2021-127983OB-C22, and PID2020-113058GB-I00 funded by MCIN/AEI/10.13039/501100011033 and by ERDF A way of making Europe and by PI21/00181 from the Instituto Carlos III. The ICN2 is funded by the CERCA programme/Generalitat de Catalunya. The ICN2 is supported by the Severo Ochoa Centres of Excellence programme, Grant CEX2021-001214-S, funded by MCIN/AEI/10.13039.501100011033. This work was also supported by the Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001214-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting Retinaldehyde Dehydrogenases to Enhance Temozolomide Therapy in Glioblastoma

  • Jiménez, Rafael
  • Constantinescu, Andrada
  • Yazir, Muhube
  • Alfonso Triguero, Paula
  • Pequerul, Raquel
  • Parés, Xavier
  • Pérez-Alea, Mileidys
  • Candiota, Ana Paula
  • Farrés, Jaume
  • Lorenzo, Julia
Glioblastoma (GB) is an aggressive malignant central nervous system tumor that is currently incurable. One of the main pitfalls of GB treatment is resistance to the chemotherapeutic standard of care, temozolomide (TMZ). The role of aldehyde dehydrogenases (ALDHs) in the glioma stem cell (GSC) subpopulation has been related to chemoresistance. ALDHs take part in processes such as cell proliferation, differentiation, invasiveness or metastasis and have been studied as pharmacological targets in cancer treatment. In the present work, three novel α,β-acetylenic amino thiolester compounds, with demonstrated efficacy as ALDH inhibitors, were tested in vitro on a panel of six human GB cell lines and one murine GB cell line. Firstly, the expression of the ALDH1A isoforms was assessed, and then inhibitors were tested for their cytotoxicity and their ability to inhibit cellular ALDH activity. Drug combination assays with TMZ were performed, as well as an assessment of the cell death mechanism and generation of ROS. A knockout of several ALDH genes was carried out in one of the human GB cell lines, allowing us to discuss their role in cell proliferation, migration capacity and resistance to treatment. Our results strongly suggest that ALDH inhibitors could be an interesting approach in the treatment of GB, with EC50 values in the order of micromolar, decreasing ALDH activity in GB cell lines to 40–50%., This research was funded by the Spanish Ministerio de Ciencia e Innovación (Agencia Estatal de Investigación, grant numbers PID2020-119424RB-I00, PID2020-113058GB-I00, PID2021-127983OB-C22/AEI/10.13039/501100011033). This research was also supported by Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, grup consolidat N-TETRASCAN 2021SGR00135). R.P. obtained financial support from the company Advanced BioDesign through a research contract agreement with Universitat Autònoma de Barcelona. This work was also supported by Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN [https://www.ciber-bbn.es/en, accessed on 26 August 2024], CB06/01/0010), an initiative of the Instituto de Salud Carlos III (Spain). R.J. was a recipient of a PIF predoctoral fellowship from Universitat Autònoma de Barcelona., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synthesis and Relaxivity study of amino acid-branched radical dendrimers as MRI contrast agents for potential brain tumor imaging

  • Wu, Yufei
  • Lloveras, Vega
  • Lope Piedrafita, Silvia
  • Mulero Acevedo, Marta
  • Candiota, Ana Paula
  • Vidal Gancedo, José
This study introduces a series of water-soluble radical dendrimers (G0 to G5) as promising magnetic resonance imaging (MRI) contrast agents that could potentially address clinical safety concerns associated with current gadolinium-based contrast agents. By using a simplified synthetic approach based on a cyclotriphosphazene core and lysine-derived branching units, we successfully developed a G5 dendrimer containing up to 192 units of 2,2,6,6-Tetramethylpiperidinyloxy (TEMPO) radical. This synthesis offers advantages including ease of preparation, purification, and tunable water solubility through the incorporation of glutamic acid anion residues. Comprehensive characterization using 1H NMR, FT-IR, and SEC-HPLC confirmed the dendrimers' structures and purity. Electron paramagnetic resonance (EPR) spectroscopy revealed that TEMPO groups in higher generation dendrimers exhibited decreased mobility and stronger spin exchange in their local environments. In vitro MRI showed that relaxivity (r1) increased with higher dendrimer generations, with G5 exhibiting an exceptionally high r1 of over 24 mM-1s-1. Molecular dynamics simulations provided crucial insights into structure-property relationships, revealing the importance of water accessibility to TEMPO groups for enhancing relaxivity. Vero cell viability assay demonstrated G3 and G3.5 have good biocompatibility. In vivo MRI experiments in mice demonstrated that G3.5 was excreted through the kidneys and selectively accumulated in glioblastoma tumors. STATEMENT OF SIGNIFICANCE: This study explores a class of MRI contrast agents based on organic radical dendrimers as a potential alternative to gadolinium-based agents. We present a simplified synthesis method for water-soluble dendrimers containing up to 192 TEMPO radical units-the highest number achieved to date for this class of compounds-resulting in record-high relaxivity values. Our approach offers easier preparation, purification, and tunable water solubility, representing an improvement over existing methods. Through combined experimental and computational studies, we provide insights into the structure-property relationships governing relaxivity. In vivo experiments demonstrate the dendrimers' potential for glioblastoma imaging, with predominantly renal excretion. This work represents a step towards developing metal-free MRI contrast agents with promising relaxivity and biocompatibility, potentially opening new avenues for diagnostic imaging research., This work was funded by Ministerio de Ciencia, Innovación y Universidades (MICIU) (PID2022-137332OB-I00 and Severo Ochoa FUNFUTURE-FIP-2020 Viraden FYP-3 projects), Generalitat de Catalunya (2021 SGR 00438), CIBER-BBN (BBN23PIV01 project) and Intramural CSIC project (202360E61). ICMAB acknowledges Spanish MICIU through the Severo Ochoa Centres of Excellence Programme Grant CEX2019-000917-S and CEX2023-001263-S. A.P.C. received funding from the MICIU grants TRIBUTE (PID2020-113058GB-I00/AEI/10.13039/501100011033) and TIMER-GLIO (PID2023-147750NB-I00). We acknowledge Bioservice of ICMAB for the cell viability assays. Yufei Wu acknowledges his China Scholarship Council (CSC) grant., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2023-001263-S)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2019-000917-S)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Synthesis and Validation of a Bioinspired Catechol-Functionalized Pt(IV) Prodrug for Preclinical Intranasal Glioblastoma Treatment

  • Mao, Xiaoman
  • Wu, Shuang|||0000-0001-7618-5476
  • Calero-Perez, Pilar|||0000-0001-9370-3757
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Alfonso Triguero, Paula|||0000-0002-6554-5656
  • Bruna, Jordi|||0000-0001-6895-5047
  • Yuste, Victor José|||0000-0001-5322-9261
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Novio, Fernando|||0000-0002-1517-3612
  • Ruiz-Molina, Daniel|||0000-0002-6844-8421
Glioblastoma is the most malignant and frequently occurring type of brain tumors in adults. Its treatment has been greatly hampered by the difficulty to achieve effective therapeutic concentration in the tumor sites due to its location and the blood-brain barrier. Intranasal administration has emerged as an alternative for drug delivery into the brain though mucopenetration, and rapid mucociliary clearance still remains an issue to be solved before its implementation. To address these issues, based on the intriguing properties of proteins secreted by mussels, polyphenol and catechol functionalization has already been used to promote mucopenetration, intranasal delivery and transport across the blood-brain barrier. Thus, herein we report the synthesis and study of complex 1, a Pt(IV) prodrug functionalized with catecholic moieties. This complex considerably augmented solubility in contrast to cisplatin and showed a comparable cytotoxic effect on cisplatin in HeLa, 1Br3G and GL261 cells. Furthermore, preclinical in vivo therapy using the intranasal administration route suggested that it can reach the brain and inhibit the growth of orthotopic GL261 glioblastoma. These results open new opportunities for catechol-bearing anticancer prodrugs in the treatment for brain tumors via intranasal administration.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Establishing Imaging Biomarkers of Host Immune System Efficacy during Glioblastoma Therapy Response, challenges, Obstacles and Future Perspectives

  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
This hypothesis proposal addresses three major questions: (1) Why do we need imaging biomarkers for assessing the efficacy of immune system participation in glioblastoma therapy response? (2) Why are they not available yet? and (3) How can we produce them? We summarize the literature data supporting the claim that the immune system is behind the efficacy of most successful glioblastoma therapies but, unfortunately, there are no current short-term imaging biomarkers of its activity. We also discuss how using an immunocompetent murine model of glioblastoma, allowing the cure of mice and the generation of immune memory, provides a suitable framework for glioblastoma therapy response biomarker studies. Both magnetic resonance imaging and magnetic resonance-based metabolomic data (i.e., magnetic resonance spectroscopic imaging) can provide non-invasive assessments of such a system. A predictor based in nosological images, generated from magnetic resonance spectroscopic imaging analyses and their oscillatory patterns, should be translational to clinics. We also review hurdles that may explain why such an oscillatory biomarker was not reported in previous imaging glioblastoma work. Single shot explorations that neglect short-term oscillatory behavior derived from immune system attack on tumors may mislead actual response extent detection. Finally, we consider improvements required to properly predict immune system-mediated early response (1-2 weeks) to therapy. The sensible use of improved biomarkers may enable translatable evidence-based therapeutic protocols, with the possibility of extending preclinical results to human patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Intranasal Administration of Catechol-Based Pt(IV) Coordination Polymer Nanoparticles for Glioblastoma Therapy

  • Mao, Xiaoman
  • Calero-Perez, Pilar|||0000-0001-9370-3757
  • Montpeyó, David|||0000-0002-0327-2015
  • Bruna, Jordi|||0000-0001-6895-5047
  • Yuste, Victor José|||0000-0001-5322-9261
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Novio, Fernando|||0000-0002-1517-3612
  • Ruiz-Molina, Daniel|||0000-0002-6844-8421
Cisplatin has been described as a potent anticancer agent for decades. However, in the case of glioblastomas, it is only considered a rescue treatment applied after the failure of second-line treatments. Herein, based on the versatility offered by coordination chemistry, we engineered nanoparticles by reaction of a platinum (IV) prodrug and iron metal ions showing in vitro dual pH- and redox-sensitivity, controlled release and comparable cytotoxicity to cisplatin against HeLa and GL261 cells. In vivo intranasal administration in orthotopic preclinical GL261 glioblastoma tumor-bearing mice demonstrated increased accumulation of platinum in tumors, leading in some cases to complete cure and prolonged survival of the tested cohort. This was corroborated by a magnetic resonance imaging follow-up, thus opening new opportunities for intranasal glioblastoma therapies while minimizing side effects. The findings derived from this research showed the potentiality of this approach as a novel therapy for glioblastoma treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Metal-Free Radical Dendrimers as MRI Contrast Agents for Glioblastoma Diagnosis, Ex Vivo and In Vivo Approaches

  • Zhang, Songbai|||0000-0003-1084-6483
  • Lloveras Monserrat, Vega|||0000-0002-9653-3340
  • Lope-Piedrafita, Silvia|||0000-0002-8127-6425
  • Calero-Perez, Pilar|||0000-0001-9370-3757
  • Wu, Shuang|||0000-0001-7618-5476
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Vidal-Gancedo, José|||0000-0002-1853-9675
Simultaneously being a nonradiative and noninvasive technique makes magnetic resonance imaging (MRI) one of the highly required imaging approaches for the early diagnosis and follow-up of tumors, specifically for brain cancer. Paramagnetic gadolinium (Gd)-based contrast agents (CAs) are the most widely used ones in brain MRI acquisitions with special interest when assessing blood-brain barrier (BBB) integrity, a characteristic of high-grade tumors. However, alternatives to Gd-based contrast agents (CAs) are highly required to overcome their established toxicity. Organic radicals anchored on a dendrimer macromolecule surface (radical dendrimers) are promising alternatives since they also exhibit paramagnetic properties and can act as T CAs like Gd-based CAs while being organic species (mitigating concerns about toxic metal accumulation). Here, we studied the third generation of a water-soluble family of poly(phosphorhydrazone) radical dendrimers, with 48 PROXYL radical units anchored on their branches, exploring their potential of ex vivo and in vivo contrast enhancement in brain tumors (in particular, of immunocompetent, orthotopic GL261 murine glioblastoma (GB)). Remarkably, this radical species provides suitable contrast enhancement on murine GL261 GB tumors, which was comparable to that of commercial Gd-based CAs (at standard dose 0.1 mmol/kg), even at its 4 times lower administered dose (0.025 mmol/kg). Importantly, no signs of toxicity were detected in vivo. In addition, it showed a selective accumulation in brain tumor tissues, exhibiting longer retention within the tumor, which allows performing imaging acquisition over longer time frames (≥2.5 h) as opposed to Gd chelates. Finally, we observed high stability of the radicals in biological media, on the order of hours instead of minutes, characteristic of the isolated radicals. All of these features allow us to suggest that the G3-Tyr-PROXYL-ONa radical dendrimer could be a viable alternative to metal-based MRI contrast agents, particularly on MRI analysis of GB, representing, to the best of our knowledge, the first case of organic radical species used for this purpose and one of the very few examples of these types of radical species working as MRI CAs in vivo.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Advances in preclinical/clinical glioblastoma treatment, can nanoparticles be of help?

  • Ruiz-Molina, Daniel|||0000-0002-6844-8421
  • Mao, Xiaoman
  • Alfonso Triguero, Paula|||0000-0002-6554-5656
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Bruna, Jordi|||0000-0001-6895-5047
  • Yuste, Victor José|||0000-0001-5322-9261
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Novio, Fernando|||0000-0002-1517-3612
Glioblastoma multiforme (GB) is the most aggressive and frequent primary malignant tumor in the central nervous system (CNS), with unsatisfactory and challenging treatment nowadays. Current standard of care includes surgical resection followed by chemotherapy and radiotherapy. However, these treatments do not much improve the overall survival of GB patients, which is still below two years (the 5-year survival rate is below 7%). Despite various approaches having been followed to increase the release of anticancer drugs into the brain, few of them demonstrated a significant success, as the blood brain barrier (BBB) still restricts its uptake, thus limiting the therapeutic options. Therefore, enormous efforts are being devoted to the development of novel nanomedicines with the ability to cross the BBB and specifically target the cancer cells. In this context, the use of nanoparticles represents a promising non-invasive route, allowing to evade BBB and reducing systemic concentration of drugs and, hence, side effects. In this review, we revise with a critical view the different families of nanoparticles and approaches followed so far with this aim.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Proximity Mapping of CCP6 Reveals Its Association with Centrosome Organization and Cilium Assembly

  • Rodriguez-Calado, Sergi|||0000-0002-8849-1101
  • Van Damme, Petra|||0000-0001-9090-027X
  • Avilés, Francesc Xavier|||0000-0002-1399-6789
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Tanco, Sebastián Martín|||0000-0003-2130-4401
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
The cytosolic carboxypeptidase 6 (CCP6) catalyzes the deglutamylation of polyglutamate side chains, a post-translational modification that affects proteins such as tubulins or nucleosome assembly proteins. CCP6 is involved in several cell processes, such as spermatogenesis, antiviral activity, embryonic development, and pathologies like renal adenocarcinoma. In the present work, the cellular role of CCP6 has been assessed by BioID, a proximity labeling approach for mapping physiologically relevant protein-protein interactions (PPIs) and bait proximal proteins by mass spectrometry. We used HEK 293 cells stably expressing CCP6-BirA* to identify 37 putative interactors of this enzyme. This list of CCP6 proximal proteins displayed enrichment of proteins associated with the centrosome and centriolar satellites, indicating that CCP6 could be present in the pericentriolar material. In addition, we identified cilium assembly-related proteins as putative interactors of CCP6. In addition, the CCP6 proximal partner list included five proteins associated with the Joubert syndrome, a ciliopathy linked to defects in polyglutamylation. Using the proximity ligation assay (PLA), we show that PCM1, PIBF1, and NudC are true CCP6 physical interactors. Therefore, the BioID methodology confirms the location and possible functional role of CCP6 in centrosomes and centrioles, as well as in the formation and maintenance of primary cilia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tracking Therapy Response in Glioblastoma Using 1D Convolutional Neural Networks

  • Ortega-Martorell, Sandra|||0000-0001-9927-3209
  • Olier, Iván|||0000-0002-5679-7501
  • Hernandez, Orlando
  • Restrepo-Galvis, Paula D.
  • Bellfield, Ryan A. A.|||0000-0002-9945-914X
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
Glioblastoma (GB) is a malignant brain tumour with no cure, even after the best treatment. The evaluation of a therapy response is usually based on magnetic resonance imaging (MRI), but it lacks precision in early stages, and doctors must wait several weeks until they are confident information is produced, facing an uncertain time window. Magnetic resonance spectroscopy (MRS/MRSI) can provide additional information about tumours and their environment but is not widely used in clinical settings since the spectroscopy format is not standardised as MRI is, and doctors are not familiarised with outputs/interpretation. This study aims to improve the assessment of the treatment response in GB using MRSI data and machine learning, including state-of-the-art one-dimensional convolutional neural networks. Preclinical (murine) GB data were used for developing models that successfully identified tumour regions regarding their response to treatment (or the lack thereof). These models were accurate and outperformed previous methods, potentially providing new opportunities for GB patient management. Background: Glioblastoma (GB) is a malignant brain tumour that is challenging to treat, often relapsing even after aggressive therapy. Evaluating therapy response relies on magnetic resonance imaging (MRI) following the Response Assessment in Neuro-Oncology (RANO) criteria. However, early assessment is hindered by phenomena such as pseudoprogression and pseudoresponse. Magnetic resonance spectroscopy (MRS/MRSI) provides metabolomics information but is underutilised due to a lack of familiarity and standardisation. Methods: This study explores the potential of spectroscopic imaging (MRSI) in combination with several machine learning approaches, including one-dimensional convolutional neural networks (1D-CNNs), to improve therapy response assessment. Preclinical GB (GL261-bearing mice) were studied for method optimisation and validation. Results: The proposed 1D-CNN models successfully identify different regions of tumours sampled by MRSI, i.e., normal brain (N), control/unresponsive tumour (T), and tumour responding to treatment (R). Class activation maps using Grad-CAM enabled the study of the key areas relevant to the models, providing model explainability. The generated colour-coded maps showing the N, T and R regions were highly accurate (according to Dice scores) when compared against ground truth and outperformed our previous method. Conclusions: The proposed methodology may provide new and better opportunities for therapy response assessment, potentially providing earlier hints of tumour relapsing stages.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Platinum-Based Nanoformulations for Glioblastoma Treatment, The Resurgence of Platinum Drugs?

  • Alfonso Triguero, Paula|||0000-0002-6554-5656
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Ruiz-Molina, Daniel|||0000-0002-6844-8421
  • Novio, Fernando|||0000-0002-1517-3612
Current therapies for treating Glioblastoma (GB), and brain tumours in general, are inefficient and represent numerous challenges. In addition to surgical resection, chemotherapy and radiotherapy are presently used as standards of care. However, treated patients still face a dismal prognosis with a median survival below 15-18 months. Temozolomide (TMZ) is the main chemotherapeutic agent administered; however, intrinsic or acquired resistance to TMZ contributes to the limited efficacy of this drug. To circumvent the current drawbacks in GB treatment, a large number of classical and non-classical platinum complexes have been prepared and tested for anticancer activity, especially platinum (IV)-based prodrugs. Platinum complexes, used as alkylating agents in the anticancer chemotherapy of some malignancies, are though often associated with severe systemic toxicity (i.e., neurotoxicity), especially after long-term treatments. The objective of the current developments is to produce novel nanoformulations with improved lipophilicity and passive diffusion, promoting intracellular accumulation, while reducing toxicity and optimizing the concomitant treatment of chemo-/radiotherapy. Moreover, the blood-brain barrier (BBB) prevents the access of the drugs to the brain and accumulation in tumour cells, so it represents a key challenge for GB management. The development of novel nanomedicines with the ability to (i) encapsulate Pt-based drugs and pro-drugs, (ii) cross the BBB, and (iii) specifically target cancer cells represents a promising approach to increase the therapeutic effect of the anticancer drugs and reduce undesired side effects. In this review, a critical discussion is presented concerning different families of nanoparticles able to encapsulate platinum anticancer drugs and their application for GB treatment, emphasizing their potential for increasing the effectiveness of platinum-based drugs.